Diabetes in elderly adults.

Diabetes is common in the elderly population. By the age of 75, approximately 20% of the population are afflicted with this illness. Diabetes in elderly adults is metabolically distinct from diabetes in younger patient populations, and the approach to therapy needs to be different in this age group. Diabetes is associated with substantial morbidity from macro- and microvascular complications. Several lines of evidence suggest that optimal glycemic control and risk factor modification can substantially reduce the risk of complications in elderly patients. In the past, treatment options were limited. However, recent studies have delineated several new and exciting therapeutic opportunities for elderly patients with diabetes.

[1]  C. Bulpitt,et al.  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[2]  P. F. Kauff.  Group , 2000, Elegant Design.

[3]  T. Fülöp,et al.  Effects of an oral glucose challenge on free radicals/antioxidants balance in an older population with type II diabetes. , 1999, The journals of gerontology. Series A, Biological sciences and medical sciences.

[4]  S Kumar,et al.  Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly Type 2 diabetic patients , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[5]  B. Davis,et al.  Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996, JAMA.

[6]  R. DeFronzo.  The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.

[7]  J. Morley,et al.  Utility of serum fructosamine as a measure of glycemia in young and old diabetic and non-diabetic subjects. , 1988, The American journal of medicine.

[8]  Bruce M Psaty,et al.  Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification , 1998, The Lancet.

[9]  I. Deary,et al.  Perceived symptoms of hypoglycaemia in elderly Type 2 diabetic patients treated with insulin , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[10]  L. Kuller,et al.  Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. , 2000, Diabetes.

[11]  J. Morley,et al.  Hospitalization and Mortality of Diabetes in Older Adults: A 3-year prospective study , 1998, Diabetes Care.

[12]  L. Lui,et al.  Reported and measured physical functioning in older inner-city diabetic African Americans. , 1999, The journals of gerontology. Series A, Biological sciences and medical sciences.

[13]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[14]  E. Barrett-Connor,et al.  Isolated Postchallenge Hyperglycemia and the Risk of Fatal Cardiovascular Disease in Older Women and Men: The Rancho Bernardo Study , 1998, Diabetes Care.

[15]  P. Strange,et al.  Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes. , 1999, The Journal of clinical endocrinology and metabolism.

[16]  D. Lau,et al.  Effect of acarbose on insulin sensitivity in elderly patients with diabetes. , 2000, Diabetes care.

[17]  D. Finegood,et al.  Alterations in non-insulin-mediated glucose uptake in the elderly patient with diabetes. , 1998, Diabetes.

[18]  E. Bonora,et al.  Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. , 2000, Diabetes care.

[19]  A. Zbrozek,et al.  Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia , 1997, Diabetes Care.

[20]  A. Zbrozek,et al.  Model of Complications of NIDDM: I. Model construction and assumptions , 1997, Diabetes Care.

[21]  J. Morley.  Diabetes mellitus: a major disease of older persons. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[22]  H. Ben-Ami,et al.  Drug-induced hypoglycemic coma in 102 diabetic patients. , 1999, Archives of internal medicine.

[23]  H. Tildesley,et al.  NIDDM in the elderly , 1996, Diabetes Care.

[24]  P. Savage,et al.  Antidiabetic treatment trends in a cohort of elderly people with diabetes. The cardiovascular health study, 1989-1997. , 1999, Diabetes care.

[25]  M. Pahor,et al.  Glycemic Control of Older Adults with Type 2 Diabetes: Findings from the Third National Health and Nutrition Examination Survey, 1988–1994 , 2000, Journal of the American Geriatrics Society.

[26]  R N Bergman,et al.  Role of Glucose Effectiveness in the Determination of Glucose Tolerance , 1996, Diabetes Care.

[27]  M. Harris,et al.  Undiagnosed NIDDM: Clinical and Public Health Issues , 1993, Diabetes Care.

[28]  W. Murphy,et al.  Clinical Evaluation of Serum Fructosamine in Monitoring Elderly Outpatient Diabetics , 1989, Journal of the American Geriatrics Society.

[29]  J. Hermans,et al.  Relationship between blood glucose level and mortality in Type 2 diabetes mellitus: a systematic review , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[30]  R. Hayward,et al.  Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 Diabetes , 1997, Annals of Internal Medicine.

[31]  M. Harris,et al.  Mortality in Adults With and Without Diabetes in a National Cohort of the U.S. Population, 1971–1993 , 1998, Diabetes Care.

[32]  G. Meneilly,et al.  Metabolic alterations in middle-aged and elderly obese patients with type 2 diabetes. , 1999, Diabetes care.

[33]  R. Brodows,et al.  A Comparison of Premixed Insulin Preparations in Elderly Patients: Efficacy of 70/30 and 50/50 human insulin mixtures , 1995, Diabetes Care.

[34]  P. Savage,et al.  Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria , 1999, The Lancet.

[35]  A J Sinclair,et al.  Mortality in older people with diabetes mellitus , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[36]  P. Tariot,et al.  Diabetes and Dementia in Long‐Term Care , 1999, Journal of the American Geriatrics Society.

[37]  M. Burge,et al.  Low-dose epinephrine supports plasma glucose in fasted elderly patients with type 2 diabetes. , 2000, Metabolism: clinical and experimental.

[38]  B. Wolffenbuttel,et al.  Comparison of Different Insulin Regimens in Elderly Patients With NIDDM , 1996, Diabetes Care.

[39]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[40]  A. Vaag,et al.  Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. , 1995, The Journal of clinical investigation.

[41]  P. Raskin,et al.  Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. , 1998, The Journal of clinical endocrinology and metabolism.

[42]  P. Raskin,et al.  Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients , 1998 .

[43]  H. Cohen,et al.  Comorbidity of five chronic health conditions in elderly community residents: determinants and impact on mortality. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[44]  R. DeFronzo.  Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. , 1988, Diabetes.

[45]  Ukpds,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes , 2002 .

[46]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[47]  L. Groop,et al.  Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients. , 1985, Annals of clinical research.

[48]  K. Flegal,et al.  Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. , 2000, Diabetes care.

[49]  K. Tucker,et al.  Self-reported prevalence and health correlates of functional limitation among Massachusetts elderly Puerto Ricans, Dominicans, and non-Hispanic white neighborhood comparison group. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[50]  R. Testa,et al.  Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[51]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[52]  M. Burge,et al.  Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. , 1999, Diabetes care.

[53]  J. Altman,et al.  Transferring Aged Type 1 Diabetic Patients From Animal to Human Insulin: A randomized study , 1998, Diabetes Care.

[54]  H. Lithell,et al.  Relation Between Plasma Tumor Necrosis Factor-α and Insulin Sensitivity in Elderly Men With Non–Insulin-Dependent Diabetes Mellitus , 1998 .

[55]  Roy A Kaplan,et al.  Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study , 1998, Diabetes Care.

[56]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[57]  J. Avorn.  Benefit and cost analysis in geriatric care. Turning age discrimination into health policy. , 1984, The New England journal of medicine.

[58]  J. Floras,et al.  Insulin-mediated increase in blood flow is impaired in the elderly. , 1995, The Journal of clinical endocrinology and metabolism.

[59]  A. Gallagher,et al.  A Study of Fluoxetine in Obese Elderly Patients with Type 2 Diabetes , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[60]  E. Feskens,et al.  The contribution of chronic conditions and disabilities to poor self-rated health in elderly men. , 1999, The journals of gerontology. Series A, Biological sciences and medical sciences.

[61]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[62]  G. Meneilly,et al.  Significance of GAD positivity in elderly patients with diabetes. , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[63]  H. Lithell,et al.  Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[64]  C. Sartori,et al.  Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation. , 1999, Journal of hypertension.

[65]  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .